Form4insider filings, from the source

SEC Form 4 · accession 0001567619-18-007783

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockDec 10, 2018M10,000$13.67A174,407D
Common StockF2,F3Dec 10, 2018S969$130.58D173,438D
Common StockF2,F4Dec 10, 2018S2,001$132.09D171,437D
Common StockF2,F5Dec 10, 2018S2,104$133.00D169,333D
Common StockF2,F6Dec 10, 2018S2,049$134.31D167,284D
Common StockF2,F7Dec 10, 2018S2,377$135.04D164,907D
Common StockF2,F8Dec 10, 2018S400$136.48D164,507D
Common StockDec 10, 2018S100$137.39D164,407D
Common StockDec 11, 2018M10,000$13.67A174,407D
Common StockF2,F9Dec 11, 2018S647$134.63D173,760D
Common StockF2,F10Dec 11, 2018S1,153$135.76D172,607D
Common StockF2,F11Dec 11, 2018S3,393$136.79D169,214D
Common StockF2,F12Dec 11, 2018S2,407$137.63D166,807D
Common StockF2,F13Dec 11, 2018S1,100$139.05D165,707D
Common StockF2,F14Dec 11, 2018S1,200$140.15D164,507D
Common StockDec 11, 2018S100$140.61D164,407D
Common Stockholding———30,000IBy Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F15$13.67Dec 10, 2018M10,000D—Dec 18, 2024Common Stock10,000328,514D
Employee Stock Option (Right to Buy)F15$13.67Dec 11, 2018M10,000D—Dec 18, 2024Common Stock10,000318,514D

Explanation of responses